BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34484239)

  • 1. PopCover-2.0. Improved Selection of Peptide Sets With Optimal HLA and Pathogen Diversity Coverage.
    Nilsson JB; Grifoni A; Tarke A; Sette A; Nielsen M
    Front Immunol; 2021; 12():728936. PubMed ID: 34484239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Proteome-Wide Immunoinformatics Tool to Accelerate T-Cell Epitope Discovery and Vaccine Design in the Context of Emerging Infectious Diseases: An Ethnicity-Oriented Approach.
    Oyarzun P; Kashyap M; Fica V; Salas-Burgos A; Gonzalez-Galarza FF; McCabe A; Jones AR; Middleton D; Kobe B
    Front Immunol; 2021; 12():598778. PubMed ID: 33717077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Systematic, Unbiased Mapping of CD8
    Stryhn A; Kongsgaard M; Rasmussen M; Harndahl MN; Østerbye T; Bassi MR; Thybo S; Gabriel M; Hansen MB; Nielsen M; Christensen JP; Randrup Thomsen A; Buus S
    Front Immunol; 2020; 11():1836. PubMed ID: 32983097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence-based prediction of SARS-CoV-2 vaccine targets using a mass spectrometry-based bioinformatics predictor identifies immunogenic T cell epitopes.
    Poran A; Harjanto D; Malloy M; Arieta CM; Rothenberg DA; Lenkala D; van Buuren MM; Addona TA; Rooney MS; Srinivasan L; Gaynor RB
    Genome Med; 2020 Aug; 12(1):70. PubMed ID: 32791978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 coronavirus vaccine T cell epitope prediction analysis based on distributions of HLA class I loci (HLA-A, -B, -C) across global populations.
    Cun Y; Li C; Shi L; Sun M; Dai S; Sun L; Shi L; Yao Y
    Hum Vaccin Immunother; 2021 Apr; 17(4):1097-1108. PubMed ID: 33175614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of HIV-specific CD4+ T cell responses against peptides selected with broad population and pathogen coverage.
    Buggert M; Norström MM; Czarnecki C; Tupin E; Luo M; Gyllensten K; Sönnerborg A; Lundegaard C; Lund O; Nielsen M; Karlsson AC
    PLoS One; 2012; 7(7):e39874. PubMed ID: 22792193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Large-Scale Identification of T-Cell Epitopes Derived From Severe Acute Respiratory Syndrome Coronavirus 2 for the Development of Peptide Vaccines Against Coronavirus Disease 2019.
    Ma Y; Liu F; Lin T; Chen L; Jiang A; Tian G; Nielsen M; Wang M
    J Infect Dis; 2021 Sep; 224(6):956-966. PubMed ID: 34145459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of peptide selection approaches for epitope-based vaccine design.
    Schubert B; Lund O; Nielsen M
    Tissue Antigens; 2013 Oct; 82(4):243-51. PubMed ID: 24461003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Novel Candidate Epitopes on SARS-CoV-2 Proteins for South America: A Review of HLA Frequencies by Country.
    Requena D; Médico A; Chacón RD; Ramírez M; Marín-Sánchez O
    Front Immunol; 2020; 11():2008. PubMed ID: 33013857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequence conservation analysis and in silico human leukocyte antigen-peptide binding predictions for the Mtb72F and M72 tuberculosis candidate vaccine antigens.
    Mortier MC; Jongert E; Mettens P; Ruelle JL
    BMC Immunol; 2015 Oct; 16():63. PubMed ID: 26493839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Landscape and selection of vaccine epitopes in SARS-CoV-2.
    Smith CC; Olsen KS; Gentry KM; Sambade M; Beck W; Garness J; Entwistle S; Willis C; Vensko S; Woods A; Fini M; Carpenter B; Routh E; Kodysh J; O'Donnell T; Haber C; Heiss K; Stadler V; Garrison E; Sandor AM; Ting JPY; Weiss J; Krajewski K; Grant OC; Woods RJ; Heise M; Vincent BG; Rubinsteyn A
    Genome Med; 2021 Jun; 13(1):101. PubMed ID: 34127050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does immune recognition of SARS-CoV2 epitopes vary between different ethnic groups?
    Bose T; Pant N; Pinna NK; Bhar S; Dutta A; Mande SS
    Virus Res; 2021 Nov; 305():198579. PubMed ID: 34560183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity.
    Lee E; Sandgren K; Duette G; Stylianou VV; Khanna R; Eden JS; Blyth E; Gottlieb D; Cunningham AL; Palmer S
    J Virol; 2021 Feb; 95(6):. PubMed ID: 33443088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 specific memory T cell epitopes identified in COVID-19-recovered subjects.
    Zhao J; Wang L; Schank M; Dang X; Lu Z; Cao D; Khanal S; Nguyen LN; Nguyen LNT; Zhang J; Zhang Y; Adkins JL; Baird EM; Wu XY; Ning S; Gazzar ME; Moorman JP; Yao ZQ
    Virus Res; 2021 Oct; 304():198508. PubMed ID: 34329696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analyzing the effect of peptide-HLA-binding ability on the immunogenicity of potential CD8+ and CD4+ T cell epitopes in a large dataset.
    Wang S; Li J; Chen X; Wang L; Liu W; Wu Y
    Immunol Res; 2016 Aug; 64(4):908-18. PubMed ID: 27094547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PREDIVAC: CD4+ T-cell epitope prediction for vaccine design that covers 95% of HLA class II DR protein diversity.
    Oyarzún P; Ellis JJ; Bodén M; Kobe B
    BMC Bioinformatics; 2013 Feb; 14():52. PubMed ID: 23409948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of multi-epitope peptides containing HLA class-I and class-II-restricted epitopes derived from immunogenic Leishmania proteins, and evaluation of CD4+ and CD8+ T cell responses induced in cured cutaneous leishmaniasis subjects.
    Hamrouni S; Bras-Gonçalves R; Kidar A; Aoun K; Chamakh-Ayari R; Petitdidier E; Messaoudi Y; Pagniez J; Lemesre JL; Meddeb-Garnaoui A
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008093. PubMed ID: 32176691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2 leading to universal blueprints for vaccine designs.
    Malone B; Simovski B; Moliné C; Cheng J; Gheorghe M; Fontenelle H; Vardaxis I; Tennøe S; Malmberg JA; Stratford R; Clancy T
    Sci Rep; 2020 Dec; 10(1):22375. PubMed ID: 33361777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
    Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
    Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoinformatics prediction of overlapping CD8
    Fatoba AJ; Maharaj L; Adeleke VT; Okpeku M; Adeniyi AA; Adeleke MA
    Vaccine; 2021 Feb; 39(7):1111-1121. PubMed ID: 33478794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.